BMS-1
25 mg
| 99.81%
TargetMol
PD1-PD-L1 inhibitor 1 (PD1-PD-L1-IN-1) is an inhibitor of the PD1-PD-L1 protein-protein interaction. It also acts as an immunomodulator. Programmed death ligand 1 (PD-L1) is a protein in humans that is encoded by the CD274 gene and the upregulation of PD-L1 allows Ys to evade the host immune system. High tumor expression of PD-L1 was associated […]
More Information
Supplier Page
KS176
100 mg
| 99.55%
TargetMol
KS176 is a potent and selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter, showing no inhibitory activity against P-gp or MRP1.
More Information
Supplier Page
TargetMol
VU0155041 is an effective and positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50: 798/693 nM, at human/rat).
More Information
Supplier Page
TargetMol
VU0155041 is an effective and positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50: 798/693 nM, at human/rat).
More Information
Supplier Page
TargetMol
VU0155041 is an effective and positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50: 798/693 nM, at human/rat).
More Information
Supplier Page
TargetMol
VU0155041 is an effective and positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50: 798/693 nM, at human/rat).
More Information
Supplier Page
TargetMol
VU0155041 is an effective and positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50: 798/693 nM, at human/rat).
More Information
Supplier Page
TargetMol
KS176
10 mg
| 99.55%
TargetMol
KS176 is a potent and selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter, showing no inhibitory activity against P-gp or MRP1.
More Information
Supplier Page
KS176
25 mg
| 99.55%
TargetMol
KS176 is a potent and selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter, showing no inhibitory activity against P-gp or MRP1.
More Information
Supplier Page